O'Sullivan Denis P, Steinkoenig Ingrid
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. D.P. O'Sullivan, BE, Our Lady's Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; I. Steinkoenig, BA, Cleveland Clinic, Cleveland, Ohio, USA. DPO and IS have no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. D. O'Sullivan, Our Lady's Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland. Email:
J Rheumatol. 2021 Mar 1. doi: 10.3899/jrheum.201680.
Eleven Patient Research Partners (PRPs) attended the virtual Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 Annual Meeting. PRPs fully participated in the panel discussion at the 2020 GRAPPA Annual Meeting on the topic of the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2). The members of the PRP group have been involved in many GRAPPA projects over the last year, including work on the GRAPPA-Outcome Measures in Rheumatology (OMERACT) Core Set, GRAPPA's 2020 Treatment Guidelines update project, and GRAPPA's Collaborative Research Network project.
11名患者研究伙伴（PRP）参加了银屑病和银屑病关节炎研究与评估小组（GRAPPA）2020年虚拟年会。PRP充分参与了2020年GRAPPA年会上关于2019冠状病毒病（COVID-19；由严重急性呼吸综合征冠状病毒2[SARS-CoV-2]引起）主题的小组讨论。在过去一年中，PRP小组的成员参与了许多GRAPPA项目，包括风湿病结局测量（OMERACT）核心集项目、GRAPPA 2020年治疗指南更新项目以及GRAPPA合作研究网络项目。
